Choudhury Saiara, Taweesedt Pahnwat T, Dadhwal Rahul, Surani Salim
Internal Medicine, Corpus Christi Medical Center, Corpus Christi, USA.
Pulmonary Medicine, Corpus Christi Medical Center, Corpus Christi, USA.
Cureus. 2021 Jul 25;13(7):e16626. doi: 10.7759/cureus.16626. eCollection 2021 Jul.
Idiopathic pulmonary fibrosis is a chronic and progressive disease with a significant mortality rate. Pirfenidone is one of two oral antifibrotic therapies approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone helps decrease disease progression in patients with IPF and reduces vital capacity. This has led to widespread use of this medication in recent years. In this case report, we present a 60-year-old male who started treatment with pirfenidone for IPF and had severe skin reactions after initiation of therapy.
特发性肺纤维化是一种慢性进行性疾病,死亡率较高。吡非尼酮是被批准用于治疗特发性肺纤维化(IPF)的两种口服抗纤维化疗法之一。吡非尼酮有助于减缓IPF患者的疾病进展,并降低肺活量。这使得该药物近年来得到广泛应用。在本病例报告中,我们介绍了一名60岁男性,他开始使用吡非尼酮治疗IPF,治疗开始后出现了严重的皮肤反应。